Stocks
Denali Therapeutics (DNLI) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -769.1% | 18.7% | -590.1% | -304.6% | -54.4% | -162.6% | ||
| Changes by years, y/y, % | -733pp | +788pp | -609pp | +286pp | +250pp | +8.7% | |||
Denali Therapeutics. EBITDA margin, %
Denali Therapeutics. EBITDA margin, changes, pp
Denali Therapeutics (DNLI) EBITDA margin US GAAP (quarter values) |
||||||||
| 2022Q4 | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | LTM ? | |||
| EBITDA margin, % | ? | -984.7% | -343.8% | 58.0% | -8 806% | -42.7% | -162.6% | |
| Changes by years, y/y, % | -395pp | -191pp | +171pp | -5 847pp | +942pp | |||
| Changes by quarters, q/q, % | +1 975pp | +641pp | +402pp | -8 864pp | +8 764pp | |||
